New pill shows promise in shrinking esophageal tumors before surgery
NCT ID NCT06044311
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study tests whether adding a pill called vactosertib to standard chemoradiation can improve outcomes for people with locally advanced esophageal cancer. Participants take vactosertib for two weeks before and after standard therapy, then undergo surgery. The goal is to see if the drug helps shrink tumors and increases the chance of a complete response at surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA ESOPHAGUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
Conditions
Explore the condition pages connected to this study.